Daniel Brims analyst CANTOR FITZGERALD

Currently out of the existing stock ratings of Daniel Brims, 11 are a BUY (91.67%), 1 are a HOLD (8.33%).

Daniel Brims

Work Performance Price Targets & Ratings Chart

Analyst Daniel Brims, currently employed at CANTOR FITZGERALD, has had 60% of price targets met with an average potential upside of 20.87%, reached in 137 days on average.

Daniel Brims has documented 24 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TTPH, Tetraphase Pharmaceuticals at 09-Sep-2015.

Wall Street Analyst Daniel Brims

Analyst best performing recommendations are on TTPH (TETRAPHASE PHARMACEUTICALS).
The best stock recommendation documented was for TTPH (TETRAPHASE PHARMACEUTICALS) on 9/9/2015. The price target of $220 was fulfilled within 9 days with a profit of $30.2 (15.91%), with a performance score of 17.68.

Average potential price target upside

TTPH Tetraphase Pharmaceuticals CMRX Chimerix MEIP MEI Pharma PRTK Paratek Pharmaceuticals MACK Merrimack Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

6 years 6 months 10 days ago
(07-May-2020)

1/2 (50%)

$36.05 (72.09%)

304

Buy Since 11-Jul-2017

$140

7 years 2 months 14 days ago
(03-Sep-2019)

0/5 (0%)

$69.6 (98.86%)

Buy Since 19-Nov-2015

$80

$420

7 years 6 months 8 days ago
(09-May-2019)

0/2 (0%)

$60 (300.00%)

Buy Since 28-Aug-2017

$80

$120

7 years 8 months 2 days ago
(15-Mar-2019)

0/9 (0%)

$51.8 (183.69%)

$140

$120

8 years 2 months 20 days ago
(28-Aug-2018)

0/3 (0%)

$69.6 (98.86%)

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Daniel Brims?

On 2014
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?